ReviewMarine drugs2018
Future Directions of Marine Myxobacterial Natural Product Discovery Inferred from Metagenomics.
Review in Marine drugs, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Unveiling the Taxonomic Diversity and Unprecedented Biosynthetic Treasure of the Phylum Myxococcota.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Article
- Genomic insights into novel predatory myxobacteria isolated from human feces.Microbiology spectrum · 2025Article
- De novo cholesterol biosynthesis in bacteria.Nature communications · 2023Article
- Article
- Myxobacteria of theMicroorganisms · 2022Article
- New Deoxyenhygrolides fromMarine drugs · 2022Article
- Global Geographic Diversity and Distribution of the Myxobacteria.Microbiology spectrum · 2021Article
- Structure and biosynthesis of sorangipyranone - a new γ-dihydropyrone from the myxobacterial strain MSr12020.Journal of industrial microbiology & biotechnology · 2021Article
- Recovery and Community Succession of theApplied and environmental microbiology · 2021Article
- Uncharted territories in the discovery of antifungal and antivirulence natural products from bacteria.Computational and structural biotechnology journal · 2021Review
- Article
- Both Soil Bacteria and Soil Chemical Property Affected the Micropredator Myxobacterial Community: Evidence from Natural Forest Soil and Greenhouse Rhizosphere Soil.Microorganisms · 2020Article
- ARTS 2.0: feature updates and expansion of the Antibiotic Resistant Target Seeker for comparative genome mining.Nucleic acids research · 2020Article
- Diversity, Ecology, and Prevalence of Antimicrobials in Nature.Frontiers in microbiology · 2019Review
- Metabolic and Biosynthetic Diversity in Marine Myxobacteria.Marine drugs · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Over the last two decades, halophilic (organisms that thrive at high salt concentrations) and halotolerant (organisms that have adapted to high salt concentrations) myxobacteria emerged as an important source of structurally diverse secondary metabolites from the marine environment. This review explores the advance of metagenomics analysis and 16S rRNA gene phylogeny of the cultured and uncultured myxobacteria from marine and other salt-environments up to July 2018. The diversity of novel groups of myxobacteria in these environments appears unprecedented, especially in the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.